u/rania_salinas

open-label extensions are not the same evidence as the randomised phase

customs_seizure_sid is right about the programme names. They are different populations with different endpoints.

Some lean mass loss accompanies weight loss in any deficit. Resistance training and adequate protein intake are the two interventions with the best evidence for limiting the proportion.

Net peptide content on the certificate was well below the purity figure and both were honest.

Agreed — and the naming problem is worse than most people here realise.

That method was developed for a different compound class and would not resolve the impurities you are asking about.

Sent an unusual compound to Medutest because nobody on this site had ever posted one. 98.6% against a claimed 98.5%.

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

Was there a point where the information was available and you did not look?

Net peptide content on the certificate was well below the purity figure and both were honest.

isabela_nilsen is right that a purity figure without a method is not comparable to one with a method.

protein and resistance training, that is the entire intervention

Adding the free proxy — track a few lifts monthly. It costs nothing and it is longitudinal.

Push back: strength dropping in a deficit is not the same as lean mass loss. Related, not identical.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

do not compare your composition to a trial average

independent purity data on this compound is thin

Three scans over eighteen months, same machine, same conditions. Only the third one made the first two interpretable.

Are you being harder on yourself than you would be on somebody else posting this?

Correcting myself: 16 weeks, not the figure I wrote. The story is the same and I had rounded it in my favour.

Small correction — the shop in that story has no independent testing on file at all, which is different from having a bad record.

the appetite effect makes eating enough protein a logistics problem

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

if nobody has tested it here, that is a fact about us, not the compound

Was there a point where the information was available and you did not look?

Stocked lines and made-to-order lines have different lead times and different storage histories. Both are ordinary; the difference is worth confirming before you commit.

How long was the randomised phase before any extension?

Bought small because the evidence base is early.

Agreed — and the endpoint definitions are where the actual claim lives.

Correction: that name covers two different molecules and the thread has been discussing both as one.

biopsy-confirmed is not the same as imaging-suggested

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

net peptide content is where the surprises live

For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.

Fat-free mass index is a ratio of fat-free mass to height squared. It moves when either term does, which makes it awkward to interpret during active weight change.

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

protein and resistance training, that is the entire intervention

a single DEXA is a number, two is a comparison, three is a trend

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

How long did it take you to notice?

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.